Celgene eyes earlier US filing for apremilast in psoriatic arthritis after positive data
This article was originally published in Scrip
Executive Summary
Celgene has shortened the timeframe in which it plans to submit a new drug application (NDA) to the US FDA for apremilast in the treatment of psoriatic arthritis (PsA) based on positive topline results from the last two of three Phase III clinical trials for its novel, oral small molecule inhibitor of phosphodiesterase 4 (PDE4).
You may also be interested in...
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.